Wall Street Zen Upgrades IQVIA (NYSE:IQV) to “Buy”

IQVIA (NYSE:IQV) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday, Wall Street Zen reports.

Several other research analysts have also recently issued reports on IQV. BMO Capital Markets raised their target price on shares of IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Stifel Nicolaus upped their price target on shares of IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. HSBC reaffirmed a “buy” rating and set a $240.00 price target on shares of IQVIA in a research report on Monday, July 6th. JPMorgan Chase & Co. boosted their price objective on IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 target price on IQVIA in a research note on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $243.62.

IQVIA Trading Up 0.1%

Shares of NYSE:IQV opened at $262.09 on Friday. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA has a 52-week low of $154.50 and a 52-week high of $271.80. The stock has a market cap of $43.14 billion, a price-to-earnings ratio of 32.52, a PEG ratio of 2.24 and a beta of 1.18. The business has a 50-day moving average price of $236.55 and a 200-day moving average price of $196.16.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. During the same quarter in the prior year, the firm earned $2.81 earnings per share. IQVIA’s revenue for the quarter was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities analysts predict that IQVIA will post 11.57 EPS for the current year.

Insiders Place Their Bets

In other news, insider Keriann Cherofsky sold 558 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the transaction, the insider directly owned 2,989 shares of the company’s stock, valued at $732,932.69. This represents a 15.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Eric Sherbet sold 5,000 shares of the stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the transaction, the insider owned 20,999 shares in the company, valued at $5,232,110.84. This trade represents a 19.23% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 15,581 shares of company stock valued at $3,796,021. 1.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of IQV. International Assets Investment Management LLC acquired a new stake in IQVIA in the 4th quarter worth about $27,000. Compass Financial Management LLC purchased a new position in shares of IQVIA in the second quarter valued at approximately $27,000. Gilpin Wealth Management LLC purchased a new position in shares of IQVIA in the fourth quarter valued at approximately $27,000. CrossGen Wealth LLC acquired a new stake in shares of IQVIA in the fourth quarter worth approximately $28,000. Finally, Financial Freedom LLC purchased a new stake in shares of IQVIA during the first quarter worth approximately $25,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.

Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms.